Radiomic signature of the FOWARC trial predicts pathological response to neoadjuvant treatment in rectal cancer.
Zhuokai ZhuangZongchao LiuJuan LiXiaolin WangPeiyi XieFei XiongJiancong HuXiaochun MengMeijin HuangYanhong DengPing LanHuichuan YuYanxin LuoPublished in: Journal of translational medicine (2021)
The CT-based radiomic models we constructed may provide a useful and reliable tool to predict pCR after neoadjuvant treatment, identify patients that are appropriate for a 'watch and wait' approach, and thus avoid overtreatment. Moreover, the CT-based radiomic signature may add predictive value to the MRI-based models for clinical decision making.
Keyphrases
- rectal cancer
- locally advanced
- contrast enhanced
- decision making
- lymph node
- end stage renal disease
- magnetic resonance imaging
- computed tomography
- newly diagnosed
- clinical trial
- randomized controlled trial
- study protocol
- squamous cell carcinoma
- peritoneal dialysis
- radiation therapy
- wastewater treatment
- combination therapy
- phase iii
- patient reported outcomes
- patient reported
- diffusion weighted imaging